secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001517022-24-000067
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia extends vadadustat supply agreement with STA through 2032
----------------------------------------------------------------

- Amendment #1 to Supply Agreement with STA extended term to January 1, 2032.
- Volume-based pricing structure and other provisions related to vadadustat drug product amended.
- Original Supply Agreement entered February 10, 2021 for manufacturing of vadadustat.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000067/0001517022-24-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000067/akba-20241015.htm
  HTML page:      https://secwatch.observer/filing/0001517022-24-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer